[{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Pharma Files First Investigational New Drug Application with The U.S. FDA for Natural Killer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kreos","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"$5.9 million","newsHeadline":"Kiadis Announces the Placement of \u20ac5 Million Convertible Bonds with Kreos","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Sanofi"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Enters a Loan Agreement of up to \u20ac25 Million with the European Investment Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Strengthens Global IP Protection for its Novel Invir.IO\u2122 Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Transgene"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,466.5 million","upfrontCash":"$26.6 million","newsHeadline":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Innate Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
IND supports the Company’s planned NK-REALM Phase 1/2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT).
Sanofi and Innate entered into a research collaboration and licensing agreement for the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi’s proprietary bispecific antibody format as well as tumor targets.
VVcopTK-RRis a large capacity Vaccinia virus Copenhagen strain genetically modified with the
double deletion TK-RR- which restricts the viral replication to tumor cells only.
Lead Product(s):
Genetically modified Vaccinia virus Copenhagen